Charles River Laboratories International, Inc. CRL shared today its outlook for its business, highlighting its unique portfolio in the industry, which is well aligned with clients' increasing demand for integrated offerings from discovery through preclinical development. The Company also announced that it is intensifying its focus on four key initiatives to drive increased shareholder value, and provided guidance for 2011.
The four key initiatives are centered on optimizing returns for shareholders, as follows:
Improving the consolidated operating margin
Improving free cash flow generation
Disciplined investment in growth businesses
Returning value to shareholders
The Company is updating its forward-looking guidance for 2010, which was previously provided on November 3, 2010, to reflect its intention to pursue strategic alternatives for its U.S. Phase I clinic. The Company intends to treat the Phase I clinical business as a discontinued operation for accounting purposes, and therefore, its results will be excluded from sales and earnings per share on a continuing basis. The result of this change impacts 2010 sales and earnings per share guidance as follows:
Revised guidance
SALES: $1,115 - $1,125 vs $1,135 to $1,145 prior
GAAP EPS: $0.28-$0.33 vs. $0.25-$0.30 prior
NON-GAAP EPS: $1.88 - $1.93 vs. $1.85-$1.90 prior
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in